AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04239248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EEN intervention group
Description: Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
Study NCT01603017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI therapy
Description: 5 treatments with magnetic field delivered to knee (n=50)
Study NCT01603017 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI therapy (off)
Description: 5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
Study NCT01641484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local control at 19.8Gy
Description: Day 14, full body TEP and pelvis MRI
Study NCT04008914 — intervention group
Intervention type: OTHER
Intervention: retrospective observation
Description: Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
Study NCT02734329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic partial nephrectomy
Description: renal artery will be clamped during surgery.
Study NCT02734329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)
Study NCT00795028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care for people after hip fracture
Study NCT00795028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care + exercise intervention
Study NCT02115321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
Study NCT02115321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
Study NCT02115321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
Study NCT02313363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patient-centered smartphone-based diabetes care system
Description: patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
Study NCT00378716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study NCT05918614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT05918614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT04701879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spine decompression with core stability exercises
Description: * 50 minutes per session~* Decompression with core stability on alternate days for 8 visits.
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam
Description: Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilastatin
Description: Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin
Description: Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study NCT04701879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine decompression
Description: 40 minutes per session~-Decompression therapy on alternate days for 8 visits.
Study NCT03264261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training
Description: robotic training, 3 times/week for 6 weeks
Study NCT03264261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill training
Description: treadmill training only, 3 times/week for 6 weeks
Study NCT02290067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose monitoring system (Omnitest 3)
Study NCT03444870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered as per the schedule specified in the respective arm.
Study NCT03444870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study NCT00657124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aminolevan EN
Description: The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
Study NCT00657124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02290067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5)
Study NCT02290067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5D)
Study NCT00280319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy for groups
Description: psychotherapy
Study NCT00378716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00378716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur
Study NCT00378716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uracil
Study NCT02384252 — intervention group
Intervention type: OTHER
Intervention: functional tissu atrial analysis
Study NCT01956019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scanning
Study NCT04263428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Irregular sleep
Description: Experimental-induced sleep variability
Study NCT03647046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Scleral Lens
Description: A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
Study NCT02254018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study NCT03508687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg Gemcabene
Description: 300mg Gemcabene
Study NCT03508687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg Gemcabene
Description: 600mg Gemcabene
Study NCT03966846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Study NCT03966846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Study NCT03861663 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
Study NCT04734119 — intervention group
Intervention type: OTHER
Intervention: Pre operative evaluation and anesthesia administration by the same anesthesiologist
Description: Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
Study NCT01460901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR modified Tri-virus specific cytotoxic t-cells
Description: This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
Study NCT02784782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthesis
Study NCT02784782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No orthesis
Study NCT02710513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucans
Description: 2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
Study NCT02867657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Five days MBSR curriculum with meditation and yoga
Study NCT00280319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: creative play therapy
Description: consisted of play activities
Study NCT03377244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBHS
Description: Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
Study NCT03377244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBHS Policy
Description: Church-level policy changes that encourages participants to engage in healthy behaviors.
Study NCT02867657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Five days MBSR curriculum with meditation and yoga
Study NCT04079127 — intervention group
Intervention type: DEVICE
Intervention: Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.
Description: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
Study NCT02357342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: intravitreal injection
Study NCT02357342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care intravitreal injections of anti-VEGF
Description: intravitreal injections of anti-VEGF
Study NCT03377244 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WORD DPP
Description: Faith based diabetes curriculum that teaches participants to connect faith and health.
Study NCT02467946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adcetris-Levact
Description: Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
Study NCT00174785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronedarone (SR33589)
Description: oral administration (tablets)
Study NCT01853410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gekoTM
Study NCT00043537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children (SET-C)
Study NCT00174785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets)
Study NCT03698188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin
Description: A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
Study NCT03698188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
Study NCT03619291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: walking on a treadmill at moderate intensity, total duration 15 minutes
Study NCT03619291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity functional training
Description: functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
Study NCT03619291 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: physical inactivity, reading sports science literature, total duration 15 minutes
Study NCT01724112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally
Study NCT01724112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00043537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT00043537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Study NCT00303875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary and exercise intervention
Study NCT01857648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: Home visits including physical activity promotion by the trained Community Health Workers.
Study NCT03608904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
Study NCT03608904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spoken word (language) listening
Description: Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
Study NCT01656317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early multidisciplinary rehabilitation
Description: Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist.
Study NCT02867449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Metacognitive Therapy for OCD according to Wells (1997)
Study NCT02867449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
Study NCT04084626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: 2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age >=18 years).
Study NCT04084626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age>=18years), day 1-14.
Study NCT02490917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT™ device
Description: Implantation of the Adjustable Continence Therapy device ACT®
Study NCT02490917 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AMS 800 ™ device
Description: Implantation of the artificial urinary sphincter AMS 800 ™
Study NCT01885858 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Indigenous profile
Description: Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
Study NCT01885858 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mestizo profile
Description: Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazobactam
Description: Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
Study NCT01868711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT02293902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Dispensed according to local practice.
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Dispensed according to local practice.
Study NCT02293902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Dispensed according to local practice.
Study NCT01868711 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavior Therapy
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
Study NCT02493764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
Study NCT03218917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Description: Administered once per day for 24 weeks
Study NCT00918086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D pill
Description: Oral tablet taken for 16 weeks
Study NCT00918086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive pill that looks and tastes like the Vitamin D pill
Study NCT01544803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eScreen
Description: The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
Study NCT01544803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alkoholhjalpen
Description: An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
Study NCT03218917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Description: Administered once per day for 24 weeks
Study NCT03218917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once per day for 24 weeks
Study NCT03764111 — intervention group
Intervention type: DEVICE
Intervention: Large Mobile Ultrasound System
Description: 30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
Study NCT03764111 — intervention group
Intervention type: DEVICE
Intervention: Handheld Ultrasound Machine
Description: 30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.